Curis, Inc. · NASDAQ:CRIS

Curis — Investor Presentation (January 2024)

17 slides from Curis's investor presentation, January 2024

  1. Slide 1: Corporate Presentation January 2024

    Corporate Presentation January 2024

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements and Disclaimers

    Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli

  3. Slide 3: Corporate Overview

    Corporate Overview Leader of IRAK4 Inhibition; Developing Emavusertib with Broad Application in Oncology Investment Emavusertib is a novel, highly-active IRAK4 inhibitor with potential cornerstone utility in heme and solid tumors Full development program underway in front-line and end-stage AML/MDS;

  4. Slide 4: IRAK4 is a Novel Anti-Cancer Target

    IRAK4 is a Novel Anti-Cancer Target Oncogenic IRAK4 activity promotes inflammation and impairs T cell function • Upregulation of IRAK4 in tumors leads to activation of NF-κB, JNK, and MAPK1,2 • IRAK-4 upregulation is associated with increased phenotypically exhausted TILs, MDSCs, increased CD4+ T re

  5. Slide 5: Emavusertib Has A Unique Molecular Fingerprint

    Emavusertib Has A Unique Molecular Fingerprint The NCI selected emavusertib for Targeted design is specifically engineered to be best-in-class NCI-sponsored research and clinical studies of IRAK4 Emavusertib Emavusertib Kinase Interaction Map Binding Affinity FLT3 Target Kd nM IRAK4 IRAK1 12,000 IRA

  6. Slide 6: Emavusertib in Leukemia

    Emavusertib in Leukemia

  7. Slide 7: Emavusertib Has a Unique Mechanism of Action

    Emavusertib Has a Unique Mechanism of Action The two primary targets of emavusertib are independent drivers of cancer IRAK4 FLT3 spliceosome mutations drive overexpression of IRAK4-Long, which genetic mutations cause constitutive activation of FLT3 constitutively activates the myddosome, driving NF-

  8. Slide 8: Preclinical Data

    Preclinical Data Rationale for monotherapy and combination with azacitidine/venetoclax Monotherapy in IRAK4 Monotherapy in FLT3 Combination with Aza/Ven 100% “Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective means to overcome the adaptive resistance incurred when target

  9. Slide 9: Compelling Initial Clinical Data

    Emavusertib Compelling Initial Clinical Data Showing clear single agent activity where expected in AML/MDS clinical studies 8 Targeted AML Patients 7 Targeted AML Patients All comers, All dose levels w/ Spliceosome Mutation* w/ FLT3 Mutation* 100% ** ** ** 80% 0% 0% 60% Patients % Change in Marrow B

  10. Slide 10: Emavusertib in Leukemia (AML/MDS)

    Emavusertib in Leukemia (AML/MDS) The ideal candidate to address the two largest genetically-defined populations in AML/MDS Emavusertib addresses the two largest genetically-defined populations in AML/MDS: 1 1) IRAK4-L (>50% of population) 2 2) FLT3 (>25% of population) Next Steps TakeAim Leukemia S

  11. Slide 11: Emavusertib in Lymphoma

    Emavusertib in Lymphoma

  12. Slide 12: Emavusertib in Lymphoma

    Emavusertib in Lymphoma Combination therapy provides complimentary inhibition of two pathways that drive NF-κB NFκB Biology: Clinical Strategy: Two Pathways Drive NHL/CLL Block both pathways with Combination Therapy BCR and TLR Pathways independently drive NF-κB overactivity In preclinical testing,

  13. Slide 13: ASH 2023 Clinical Data in Lymphoma

    ASH 2023 Clinical Data in Lymphoma All patients achieved decreases in tumor burden, including multiple complete responses • 19 treated patients, 11 of whom had received prior BTKi treatment, demonstrated anti-cancer activity • Median treatment duration was 96 days (range 21-613 days), suggesting acc

  14. Slide 14: ASH 2023 Clinical Data in PCNSL

    ASH 2023 Clinical Data in PCNSL All patients achieved decreases in tumor burden, including multiple complete responses PCNSL combination with ibrutinib 0% 5 evaluable PCNSL patients previously treated with BTKi -20% demonstrated anti-cancer activity, with 3 patients achieving CR and one % Change fro

  15. Slide 15: Clinical Strategy in Lymphoma

    Clinical Strategy in Lymphoma Emavusertib is the ideal candidate to combine with BTKi to maximize downregulation of NF-κB • Patients are currently treated with BTKi because it downregulates NF-κB • Two pathways drive NF-κB: Next Steps TakeAim Lymphoma Study 1) BCR Pathway: addressed by blocking BTK

  16. Slide 16: Corporate Overview

    Corporate Overview Leader of IRAK4 Inhibition; Developing Emavusertib with Broad Application in Oncology Investment Emavusertib is a novel, highly-active IRAK4 inhibitor with potential cornerstone utility in heme and solid tumors Full development program underway in front-line and end-stage AML/MDS;

  17. Slide 17: End of Corporate Presentation

    End of Corporate Presentation NASDAQ: CRIS

Curis — Investor Presentation (January 2024) on 6ix